Cargando…

Neutrophil gelatinase–associated lipocalin as an immunomodulator in endocrine hypertension

In recent studies, primary aldosteronism (PA) has been reported as the most common etiology for secondary hypertension of endocrine origin, accounting for approximately 10% of cases. In PA, excess aldosterone production can lead to deleterious effects at the cardiovascular (CV) and renal levels by a...

Descripción completa

Detalles Bibliográficos
Autores principales: Araos, Patricio, Amador, Cristián A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640732/
https://www.ncbi.nlm.nih.gov/pubmed/36387895
http://dx.doi.org/10.3389/fendo.2022.1006790
_version_ 1784825925880250368
author Araos, Patricio
Amador, Cristián A.
author_facet Araos, Patricio
Amador, Cristián A.
author_sort Araos, Patricio
collection PubMed
description In recent studies, primary aldosteronism (PA) has been reported as the most common etiology for secondary hypertension of endocrine origin, accounting for approximately 10% of cases. In PA, excess aldosterone production can lead to deleterious effects at the cardiovascular (CV) and renal levels by activating mineralocorticoid receptors, which involves an increase in pro-inflammatory and pro-fibrotic mediators. Among these mediators, neutrophil gelatinase–associated lipocalin (NGAL), a secretion glycoprotein belonging to the lipocalin superfamily, has been closely linked to CV and renal damage in several pathological conditions. Because NGAL can be detected in biofluids such as plasma and urine, it has been proposed as a damage biomarker for target tissues and has also been studied for its role in hypertension and associated with PA. NGAL is produced by many different cell types, can be carried on extracellular vesicles, and is modulated by microRNAs, which would support its use as a biomarker for endocrine hypertension due to PA. Over the last decade, studies have shown that NGAL is necessary for the development of aldosterone-induced hypertension and that is associated with end-organ damage. In addition, it has been proposed that some mechanisms are dependent on the activation of immune cells, such as dendritic cells and macrophages, where the release of specific cytokines (i.e., interleukin [IL]-23) or chemokines (i.e., CCL-5) induced by aldosterone would depend on NGAL. Subsequently, this activates the T helper (Th) lymphocytes, such as Th(17) and Th(2), resulting in CV and renal fibrosis due to the high aldosterone levels. Although the immune system has been closely associated with essential hypertension, its participation in endocrine hypertension has not been fully elucidated. This review discusses the link between NGAL and endocrine hypertension, particularly in the context of PA, and their possible regulators and mechanisms, with a focus on its role as an immunomodulator.
format Online
Article
Text
id pubmed-9640732
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96407322022-11-15 Neutrophil gelatinase–associated lipocalin as an immunomodulator in endocrine hypertension Araos, Patricio Amador, Cristián A. Front Endocrinol (Lausanne) Endocrinology In recent studies, primary aldosteronism (PA) has been reported as the most common etiology for secondary hypertension of endocrine origin, accounting for approximately 10% of cases. In PA, excess aldosterone production can lead to deleterious effects at the cardiovascular (CV) and renal levels by activating mineralocorticoid receptors, which involves an increase in pro-inflammatory and pro-fibrotic mediators. Among these mediators, neutrophil gelatinase–associated lipocalin (NGAL), a secretion glycoprotein belonging to the lipocalin superfamily, has been closely linked to CV and renal damage in several pathological conditions. Because NGAL can be detected in biofluids such as plasma and urine, it has been proposed as a damage biomarker for target tissues and has also been studied for its role in hypertension and associated with PA. NGAL is produced by many different cell types, can be carried on extracellular vesicles, and is modulated by microRNAs, which would support its use as a biomarker for endocrine hypertension due to PA. Over the last decade, studies have shown that NGAL is necessary for the development of aldosterone-induced hypertension and that is associated with end-organ damage. In addition, it has been proposed that some mechanisms are dependent on the activation of immune cells, such as dendritic cells and macrophages, where the release of specific cytokines (i.e., interleukin [IL]-23) or chemokines (i.e., CCL-5) induced by aldosterone would depend on NGAL. Subsequently, this activates the T helper (Th) lymphocytes, such as Th(17) and Th(2), resulting in CV and renal fibrosis due to the high aldosterone levels. Although the immune system has been closely associated with essential hypertension, its participation in endocrine hypertension has not been fully elucidated. This review discusses the link between NGAL and endocrine hypertension, particularly in the context of PA, and their possible regulators and mechanisms, with a focus on its role as an immunomodulator. Frontiers Media S.A. 2022-10-25 /pmc/articles/PMC9640732/ /pubmed/36387895 http://dx.doi.org/10.3389/fendo.2022.1006790 Text en Copyright © 2022 Araos and Amador https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Araos, Patricio
Amador, Cristián A.
Neutrophil gelatinase–associated lipocalin as an immunomodulator in endocrine hypertension
title Neutrophil gelatinase–associated lipocalin as an immunomodulator in endocrine hypertension
title_full Neutrophil gelatinase–associated lipocalin as an immunomodulator in endocrine hypertension
title_fullStr Neutrophil gelatinase–associated lipocalin as an immunomodulator in endocrine hypertension
title_full_unstemmed Neutrophil gelatinase–associated lipocalin as an immunomodulator in endocrine hypertension
title_short Neutrophil gelatinase–associated lipocalin as an immunomodulator in endocrine hypertension
title_sort neutrophil gelatinase–associated lipocalin as an immunomodulator in endocrine hypertension
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640732/
https://www.ncbi.nlm.nih.gov/pubmed/36387895
http://dx.doi.org/10.3389/fendo.2022.1006790
work_keys_str_mv AT araospatricio neutrophilgelatinaseassociatedlipocalinasanimmunomodulatorinendocrinehypertension
AT amadorcristiana neutrophilgelatinaseassociatedlipocalinasanimmunomodulatorinendocrinehypertension